In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indicationsmatching the reference product Stelara ® (ustekinumab) and has granted a provisional ...
GlobalData on MSN1mon
Teva and Alvotech launch ustekinumab biosimilar injection in USSelarsdi has been approved by the US Food and Drug Administration in four presentations, aligning with the approved ...
Hosted on MSN11mon
FDA approves Alvotech biosimilar of J&J top-selling drug Stelaratop-selling drug Stelara. The biosimilar, called Selarsdi, will be marketed in the US by Alvotech partner Teva Pharmaceuticals (NYSE:TEVA) following a settlement with J&J. Teva intends to launch ...
The U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), for treating various conditions including plaque psoriasis ...
The FDA has provisionally determined that SELARSDI will be interchangeable with the reference biologic Stelara ®, following the expiration of exclusivity for the first interchangeable biosimilar ...
The FDA has provisionally determined that SELARSDI will be interchangeable with the reference biologic Stelara ®, following the expiration of exclusivity for the first interchangeable biosimilar, on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback